--Alerus Financial Keeps Quarterly Dividend at $0.21 per Share, Payable Oct. 10 to Holders of Record on Sept. 26-March 2024-www.financetom.com

Business

--Alerus Financial Keeps Quarterly Dividend at $0.21 per Share, Payable Oct. 10 to Holders of Record on Sept. 26

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

--Alerus Financial Keeps Quarterly Dividend at $0.21 per Share, Payable Oct. 10 to Holders of Record on Sept. 26

Sep 2, 2025 8:10 AM

10:54 AM EDT, 09/02/2025 (MT Newswires) --

Price: 22.19, Change: -0.09, Percent Change: -0.38

Previous page： --Digital World Acquisition Gains Ahead of Shareholder Meeting to Vote on Merger With Trump Media & Technology Group Next page： Aflac Insider Sold Shares Worth $423,105, According to a Recent SEC Filing

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

--Digital World Acquisition Gains Ahead of Shareholder Meeting to Vote on Merger With Trump Media & Technology Group

Mar 22, 2024

10:10 AM EDT, 03/22/2024 (MT Newswires) -- Price: 45.89, Change: +3.08, Percent Change: +7.19 ...

Aflac Insider Sold Shares Worth $423,105, According to a Recent SEC Filing

Mar 22, 2024

10:01 AM EDT, 03/22/2024 (MT Newswires) -- Thomas J Kenny, Director, on March 20, 2024, sold 5,000 shares in Aflac ( AFL ) for $423,105. Following the Form 4 filing with the SEC, Kenny has control over a total of 17,920 shares of the company, with 17,920 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/4977/000000497724000074/xslF345X03/wk-form4_1711113477.xml Price: 84.90, Change: -0.12, Percent Change: -0.14...

Belite Bio Completes Regulatory Submission for Tinlarebant's Clinical Trial in Japan

Mar 22, 2024

10:10 AM EDT, 03/22/2024 (MT Newswires) -- Belite Bio ( BLTE ) said Friday that it has completed the submission to Japan's Pharmaceuticals and Medical Devices Agency to start a clinical trial of its Tinlarebant product candidate in patients with Stargardt Disease. The company said the planned trial is a combination of a phase 1b study to evaluate the pharmacokinetics...

Summit Therapeutics Reports 23% Complete Response in Metastatic NSCL Cancer Drug Ivonescimab's Clinical Trials

Mar 22, 2024

10:08 AM EDT, 03/22/2024 (MT Newswires) -- Summit Therapeutics ( SMMT ) said Friday clinical trials of its investigational drug candidate ivonescimab, alone or combined with chemotherapy, led to intercranial responses among 34% of patients with brain metasteses at baseline, with 23% seeing a complete response, in its treatment for metastatic non-small cell lung cancer. The biopharmaceutical company reported the...

About

Terms and Conditions Privacy policy Cookie Settings Contact Us

Services

financetom Market Personal Finance Business Economy Cryptocurrency MAP